Business Wire

ANT-GROUP

2.8.2022 11:16:03 CEST | Business Wire | Press release

Share
Coty and Ant Group Reach Strategic partnership to Deploy Alipay+ Solution in Global Travel Retail Industry

Coty Inc. (NYSE: COTY) ("Coty"), one of the world’s leading beauty companies and global leaders in fragrance, has officially signed the Global Travel Retail Joint Business Partnership with Ant Group to enhance the cooperation in digitalization. The agreement means that Coty will be the first beauty company to reach the strategic partnership in travel retail to support digital platforms like Alipay and other digital payment methods at a global level through Alipay+, a suite of global cross-border mobile payments and marketing solutions operated by Ant Group.

Based on the partnership, Coty will continue expanding the travel retail business through the digital operation powered by Alipay+, by creating comprehensive and diversified brand campaigns via Alipay and other payment platforms, and offering more customized consumer experience with higher quality and efficiency. This strategic partnership will extend from China to a wider area of APAC, and furtherly to Coty’s global travel retail market.

In the past year, Coty's travel retail business saw an outstanding performance. The traffic and sales of brick & mortar retail stores in Hainan saw strong growth with the help of digital operation, and the duty-free business in China achieved a triple-digit growth.

Digital operation is a clear strategic focus for Coty Travel Retail to innovate online and offline shopping experiences with a traveler-centric approach. Alipay, as a leading digital open platform leveraged by over 80 million businesses serving more than 1 billion consumers, is a valuable partner of Coty to co-create the future of beauty by innovative marketing capabilities and digital payment solutions. Since 2021, Coty has partnered with Alipay together on a series of travel retail activations, including Lancaster Super Brand Day, fragrance annual award, and had “Travel Around World” campaign debut in June.

"The cooperation with Ant Group in digitalization will help us serve our customers better," Caroline Andreotti, Executive Vice President of Coty's Global Travel Retail Business , remarked at the signing ceremony. "In the future, Coty and Ant will continue to work together to explore more possibilities of digital channels to improve consumer experience. We will also aim to deliver better services and products to more consumers around the world on their travel journey, and let them enjoy a better, more convenient and sustainable future."

With the signing of this agreement, Coty will go forward hand in hand with Ant Group to boost the development of digital service as well as the travel retail business, and will continue to develop more in-depth cooperation in an all-round way, across precision marketing, omni channel activations, and digital payment solution.

Coty's travel retail department is bringing the global iconic brands and tourists’ most favorable regional brands to travel retail channels, covering prestige and consumer brands, to build a matrix that include three product categories – fragrance, makeup, and skincare. At the present, the brands that Coty’s travel retail department is operating in Asia Pacific market include: 2-axis beauty brands (covering makeup and fragrance) -- Gucci beauty and Burberry beauty; the fragrance category -- Chloe, Tiffany, Miu Miu, Marc Jacobs, Calvin Klein; and the skincare category, of which, Lancaster, founded in Monaco in 1946, is a representative among the iconic high-end skincare brands.

The skincare category, in particular, has grown exponentially in Asia and represents a huge growth opportunity for Coty Travel Retail. By launching Lancaster with an Asia-focused product line-up, Coty targets to become an even stronger global player in skincare. It features new merchandising designs and offers the Asian consumers effective, sophisticated, safe, and sustainable personal care products customized to fit their regional needs. The key markets for this new product line-up are China, Korea, Thailand, and India focusing on the key markets for the category in the travel retail industry and a strategic vector of growth for the company .

Till now, Lancaster has set up four brick & mortar retail stores in Hainan and launched an official mini program on the Alipay platform, injecting a booster into the skincare business expansion of Coty in APAC.

With innovative technologies and solutions, Alipay+ brings an easy way to capture digital-first customers and makes it more convenient for merchants to serve hundreds of millions of users of leading digital payment service providers. Especially, through a one-stop integration and simple technical adaption, merchants can access all existing and later-onboarded digital payment methods brought by Alipay+. Moreover, Alipay+ can help merchants further extend the reach of potential users through its rich marketing campaign solutions.

Facing the impact and challenge caused by the COVID-19, Alipay+ has been working with brands since 2020, to find a way out for the travel retail industry in the post-pandemic era. With the comprehensive understanding of brand business, Alipay+ is making efforts to empower digital operation and transformation of business partners, and to improve consumers’ shopping experience with its payment and marketing solutions.

About Coty, Inc.

Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. Coty serves consumers around the world, selling prestige and mass market products in more than 130 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and, we are committed to creating our own positive impact on the planet. Learn more at coty.com or on LinkedIn and Instagram.

About Ant Group and Alipay+

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

Ant Group is the owner and operator of Alipay, the leading digital platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.

Ant Group has further introduced Alipay+, a suite of global cross-border mobile payments and marketing solutions which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye